National Advertising Division Recommends AceJan Discontinue Efficacy Claims for Disinfectant Generator

NEW YORK — The National Advertising Division (NAD) of BBB National Programs announced on July 8, 2026, that it has recommended AceJan Capital LLC discontinue certain advertising claims regarding the efficacy of its hypochlorous acid (HOCl) generator. The decision followed a challenge brought by competitor Professional Disposables International, Inc. (PDI), a major manufacturer of pre-moistened wipes and infection prevention products.

The challenge targets the express and implied claims made by AceJan for its on-site generator, which produces a disinfectant solution. While the specific advertisements and claims in question were not detailed in the public announcement, the NAD's action focuses on whether the company provided adequate substantiation for its marketing messages about the product's performance.

Hypochlorous acid is a weak acid used as a disinfectant and sanitizer, often generated on-site in facilities like hospitals, schools, and offices by electrolyzing salt and water. AceJan’s product, sold under the brand name Medama, is registered with the U.S. Environmental Protection Agency (EPA), according to its product label dated May 7, 2024. This registration allows the company to make specific, EPA-approved claims, such as being a “broad spectrum disinfectant,” a “hospital level disinfectant,” and effective against bacteria like Salmonella enterica and Staphylococcus aureus.

The NAD’s recommendation suggests that AceJan’s marketing may have gone beyond the scope of these approved claims, venturing into territory that its supporting evidence could not validate. The advertising industry’s self-regulatory process is designed to address precisely these situations, where claims, even for a federally registered product, might overstate performance or imply benefits that have not been scientifically proven.

The NAD is the advertising industry’s primary self-regulatory body, providing an independent forum for resolving disputes over the truthfulness and accuracy of national advertising. Its decisions are not legally binding, but the vast majority of advertisers comply with its recommendations. Failure to do so can result in the case being referred to a government agency, such as the Federal Trade Commission (FTC), for potential enforcement action.

This system operates on challenges from competitors, consumers, or internal monitoring. The NAD then assesses whether the advertiser has a “reasonable basis” for its claims. Past NAD cases provide insight into its standards. For example, it recommended Molson Coors discontinue claims that a competitor’s light beer “tastes like water,” ruling that this was a measurable attribute requiring substantiation, not just opinion or puffery. In another case involving PerSe Beauty Inc., the NAD recommended discontinuing claims based on product reviews because it could not verify how the reviews were collected and maintained, deeming the evidence unreliable.

For companies in the cleaning and disinfection space, the distinction between an EPA-registered product and the advertising claims made about it is critical. As explained by industry resources from CloroxPro, many on-site HOCl generators are classified as “devices” by the EPA and do not require pre-market registration. However, AceJan’s Medama system is EPA-registered, placing it in the category of products that have undergone a more rigorous review. The NAD’s action underscores that even with this registration, every specific marketing claim about what the product can do must be backed by solid evidence.

The recommendation from the NAD places AceJan at a crossroads. The company must decide whether to modify or pull the challenged advertising to comply with the ruling. The financial and reputational stakes are significant. Revising national marketing campaigns involves considerable cost, and an adverse finding from a body like the NAD can damage a brand’s credibility with sophisticated business-to-business customers who rely on proven efficacy for health and safety.

In our experience, companies run into regulatory trouble when marketing ambitions outpace compliance and documentation. A product launch or a new campaign creates immense pressure to make bold claims, but this is precisely when rigorous internal review is most critical. This incident serves as a clear warning that what starts as a marketing issue can quickly escalate into a significant operational and financial liability. The cost of pulling a campaign, potential FTC scrutiny, and damage to brand trust can far outweigh any initial sales lift from unsubstantiated claims.

This is why we view proactive financial risk management as an essential business process, not just a back-office function. We work with clients to build robust internal controls that ensure marketing, legal, and product development are aligned before a single ad dollar is spent. By stress-testing claims against regulatory standards and potential competitor challenges early on, businesses can avoid these costly public corrections. To learn how to integrate this level of oversight into your operations, contact C&S Finance Group LLC at csfinancegroup.com.

Looking ahead, AceJan Capital LLC has the option to appeal the NAD’s decision to the National Advertising Review Board (NARB), the appellate body for the industry’s self-regulation system. Should the company choose not to appeal, it is expected to provide a statement to the NAD outlining its compliance. Industry observers will be watching closely to see how AceJan responds and how this decision influences advertising practices among other manufacturers of on-site disinfectant generators.